Lineage Cell Therapeutics, Inc. (LCTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 5M 10M 15M FY09: 1.9M FY10: 3.7M FY11: 4.4M FY12: 3.9M FY13: 4.4M FY14: 5.2M FY15: 7M FY16: 5.9M FY17: 3.5M FY18: 5M FY19: 3.5M FY20: 1.8M FY21: 4.3M FY22: 14.7M FY23: 8.9M FY24: 9.5M FY25: 14.6M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 5M 10M 15M FY10: 3.7M FY11: 4.4M FY12: 3.5M FY13: 3.6M FY14: 4.4M FY15: 5.9M FY16: 5.6M FY17: 3.3M FY18: 4.7M FY19: 3.1M FY20: 1.4M FY21: 2.9M FY22: 14M FY23: 8.3M FY11 FY13 FY15 FY17 FY19 FY21 FY23

Operating Income Annual

-75M -50M -25M 0 25M 50M 75M FY09: -3.5M FY10: -9.9M FY11: -18.7M FY12: -25M FY13: -56M FY14: -50.7M FY15: -65.8M FY16: -59M FY17: -38.9M FY18: -41.8M FY19: -38.9M FY20: -26.4M FY21: -49.2M FY22: -22.5M FY23: -24.7M FY24: -21.5M FY25: -36.6M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-75M -50M -25M 0 25M 50M 75M FY09: -5.1M FY10: -11.2M FY11: -16.5M FY12: -21.4M FY13: -43.9M FY14: -36.4M FY15: -47M FY16: 33.6M FY17: -20M FY18: -46M FY19: -11.7M FY20: -20.6M FY21: -43M FY22: -26.3M FY23: -21.5M FY24: -18.6M FY25: -63.5M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 500K 1M 1.5M FY10: 27.7K FY11: 79.4K FY12: 434.3K FY13: 793K FY14: 837K FY15: 1.1M FY16: 358K FY17: 168K FY18: 302K FY19: 412K FY20: 385K FY21: 1.4M FY22: 728K FY23: 671K FY24: 334K FY10 FY12 FY14 FY16 FY18 FY20 FY22 FY24

Operating Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M FY09: -4.3M FY10: -7.7M FY11: -13.6M FY12: -19.7M FY13: -29.5M FY14: -38.9M FY15: -44.5M FY16: -42.3M FY17: -30.5M FY18: -30.9M FY19: -31.9M FY20: -19.8M FY21: -23.6M FY22: 1.1M FY23: -28.6M FY24: -23.1M FY25: -18.9M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M FY09: -4.3M FY10: -8M FY11: -14.6M FY12: -20.1M FY13: -31.8M FY14: -39.3M FY15: -45.8M FY16: -44.6M FY17: -31.8M FY18: -31.4M FY19: -32.4M FY20: -19.8M FY21: -23.9M FY22: 646K FY23: -29.2M FY24: -23.7M FY25: -19.4M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 80M 160M 240M FY14: 66.5M FY15: 79.7M FY16: 99.6M FY17: 114.5M FY21: 164.5M FY22: 169.8M FY23: 172.7M FY24: 200.2M FY25: 230.1M FY14 FY15 FY16 FY17 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.20 -0.80 -0.40 0.00 0.40 0.80 1.20 Q4 '10: -0.28 Q1 '11: -0.30 Q2 '11: -0.33 Q3 '11: -0.30 Q4 '11: -0.34 Q1 '12: -0.37 Q2 '12: -0.39 Q3 '12: -0.41 Q4 '12: -0.43 Q1 '13: -0.48 Q2 '13: -0.51 Q3 '13: -0.57 Q3 '14: -0.78 Q4 '14: -0.56 Q1 '18: -1.07 Q2 '18: -0.99 Q3 '18: -0.58 Q4 '18: -0.36 Q1 '19: 0.44 Q2 '19: 0.27 Q3 '19: -0.37 Q4 '19: -0.04 Q1 '20: -0.40 Q1 '22: -0.29 Q2 '22: -0.30 Q3 '22: -0.29 Q4 '22: -0.15 Q1 '23: -0.14 Q2 '23: -0.13 Q3 '23: -0.13 Q4 '23: -0.13 Q1 '24: -0.14 Q2 '24: -0.14 Q3 '24: -0.12 Q4 '24: -0.10 Q1 '25: -0.08 Q2 '25: -0.18 Q3 '25: -0.29 Q4 '25: -0.28 Q1 '26: -0.29 Q4 '11 Q1 '13 Q1 '18 Q2 '19 Q2 '22 Q3 '23 Q4 '24 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.